Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study

Table 1

Association between CD155 expression and clinical pathological features.

		Percentage of tumor cells with CD155 overexpression
Age, correlation coefficient^†	126	-0.026	0.774
Histological grade^†
I	13	5% (17%)	0.049
II	79	32% (45%)
III	26	42% (48%)
ER status^‡
Negative	31	56% (47%)	<0.001
Positive	90	21% (39%)
PR status^‡
Negative	41	35% (46%)	0.307
Positive	80	27% (43%)
HER2 overexpression^‡
Negative	63	26% (42%)	0.223
Positive	21	40% (47%)
TNM stage^†
I	30	23% (41%)	0.58
II	67	36% (46%)
III	18	21% (38%)
IV	6	50% (55%)

^†Spearman correlation test. ^‡Mann–Whitney test.